KR20050027385A - Use of agaricus brazai extract as medcinal drug and funtional food for anti-hyperglycemia - Google Patents

Abstract

Use of Agaricus blazei murrill extract is provided, which Agaricus blazei murrill extract has improved anti-hyperglycemia activity, so that it can be useful for regulation of blood glucose level and prevention of a complication in a patient suffering from hyperglycemia without side-effects, and it can be applied to the anti-hyperglycemia medicinal drug and food. A method for producing the anti-hyperglycemia food comprises adding the Agaricus blazei murrill extract as a necessary component into raw material of food, wherein the Agaricus blazei murrill extract is prepared by using a conventional extraction method. The anti-hyperglycemia food contains the Agaricus blazei murrill extract as an effective component.

Description

Use of Agaricus brazai extract as medcinal drug and funtional food for anti-hyperglycemia}

The present invention relates to a functional food having an effect on hypoglycemia and hepatic functional activity in hyperglycemic diseases caused by streptozotocin, which contains agaricus mushroom extract as an essential ingredient and its use.

Due to various changes in diet, diabetes has become one of the adult diseases that threaten the health of modern people, and recently, pediatric diabetes is rapidly increasing, which has threatened the health of children. Diabetic diseases are often obtained from the daily lives of individuals, such as overwork, stress, habitual drinking, smoking, and obesity, rather than organic causes. It is always exposed to the risk of hyperglycemia due to stress and drug abuse.

 We need energy in our daily lives. The source of energy is carbohydrates in our foods. Carbohydrates absorbed by our bodies are usually stored as glucose in the blood. It is stored in the form of fat and plays an important role in this hormone called insulin.

Insulin, produced by pancreatic beta cells, is an important hormone in our body that transfers glucose to muscle tissue or generates energy from glucose. Normal people use glucose as an energy source and insulin as a catalyst to obtain energy. It means that a failure occurs in the license.

The function of the pancreas is to send blood sugar-controlling hormones (insulin) into the blood and to send digestive enzymes such as amylase, lipase, trypsin, and alkaline fluid into the duodenum.

Diabetes is not enough to produce or function in insulin, and it is difficult to utilize the cells (glucose) intake of nutrients (glucose) even if insulin is normally secreted by the pancreatic function, which is an insulin-producing organ that changes the nutrients that can be used in the body. If it appears.

Diabetes causes serious complications over time, which is complex and complications that can be expressed as department stores of adult diseases.

In particular, it is known that diabetes mellitus is accompanied by liver dysfunction. The liver stores the nutrients absorbed by the intestine, keeps it useful when needed, stores energy (glycogen) for muscle exercise, and maintains normal blood sugar. Hepatic impairment finds a very important part of the secondary complications of diabetes. Therefore, the treatment of hyperglycemic diseases is expected to increase the therapeutic effect by activating liver function, and it is commercially available as a food to support this, and it is functional to support the hyperglycemic diseases and liver function activity from natural substances without side effects. The reality is that food is desperately needed.

In the present invention, agaricus mushroom extract was found to assist in hypoglycemic activity and hepatic function in the hyperglycemic diseases of streptozotocin-induced hyperglycemic diseases, and found to be useful for hyperglycemic diseases.

Agaricus mushroom of the present invention is known to have the efficacy of anti-cancer, anti-diabetic, anti-inflammatory, heart strengthening, blood pressure control, liver function, immune function, etc. and has been reported to be particularly excellent anti-cancer and anti-inflammatory action.

The origin of Agaricus mushrooms is called Piedate, 200km from Sao Paulo, Brazil. Locally, these mushrooms are called "Shin mushrooms" and "Sun mushrooms". In Korea, "white mushrooms" and "spirit mushrooms" Is called. The reason for the mushroom's attention was that in the 1960s, Professor WJ Sinden of Pennsylvania State University in the Americas and Dr. EB Rembrandt of the Rembrandt Research Institute conducted epidemiological investigations, indicating that indigenous people in the Piadate region had a significantly lower incidence of adult illness. They identified the agaricus mushrooms they had been eating all the time, and the two doctors conducted an ingredient study of the agaricus mushrooms to announce the surprising effect of the "antitumor" of the mushrooms. Agaricus Blaze became known as Muril. Academic studies in Japan have shown that polysaccharides such as β-D-glucan of agaricus mushrooms in the Japanese Cancer Society general assembly at Tokyo University College of Pharmacy and the National Cancer Center Research Institute activate the interferon production to increase immunity against virus invasion. Announced to prove the point.

Agaricus mushrooms grow only under limited climate and soil conditions, and the temperature at 30 ° C is 20 ° C at night, with uniform crossovers, and they do not grow without regular showers in the evening. . Protein 39.64%, Potassium 3.36%, Fiber 7.35%, Fat 3.68%, Ash 7.89%, Carbohydrate 41.40%, Phosphorus 1.01%, Dietary Sodium 46.1mg, Calcium 19.7mg, Iron 19.7mg, Vitamin B₁10.52mg, Vitamin B₂ 0.37 It contains mg, nisin 44.2mg, and ergosterol 383mg. It is richer in carbohydrates, protein, and dietary fiber than other mushrooms, and contains a lot of ergosterol, a precursor of vitamin B₁, B₂, nisin and vitamin D₂. In addition, it is rich in minerals, unsaturated fatty acids, nucleic acids, and amino acids, which are mainly composed of linoleic acid. Especially, beta-glucan, a kind of polysaccharide, activates immune function of normal cellular tissues of humans to suppress the proliferation and recurrence of cancer cells, It is known to promote the production of interglucan, interferon, which activates cell functions.

Therefore, in order to develop and utilize the fruiting bodies of Agaricus mushrooms as foods and medicines with more specific functions, it is necessary to find a clear mechanism of action through continuous research and clinical experiments, and to identify new ones with safety. .

Therefore, in this study, we compared the efficacy of hyperglycemic disease improvement effect using white paper to obtain the usefulness of Agaricus mushroom, which has been revealed through active research such as academia.

It is an object of the present invention to provide an ameliorating effect of hyperglycemic diseases of white paper induced by streptozotocin as a single agent containing agaricus mushroom extract as an essential ingredient.

  Still another object of the present invention is to provide a pharmaceutical composition having a prophylactic and therapeutic effect of hypertension, comprising the agaricus mushroom extract as the single agent. In addition, to provide a health food and its use for preventing hyperglycemia based on such a composition.

According to the above object, the configuration of the present invention is as follows.

Healthy Sprague-Dawley, weighing around 200g, was selected for a one-week stable period for environmental adaptation in the laboratory, and normal, control, agaricus mushroom extract groups (2.5g / kg), streptozo Toxin (40mg / kg), Agaricus extract group (2.5g / kg) + Streptozotocin (40mg / kg) treatment group was performed.

Normal group, control group, agaricus extract (2.5 / kg), streptozotocin (40mg / kg), agaricus extract (2.5 / kg) + streptozotocin (40mg / kg) were divided into normal group. Free dietary intake control group was saline (Nacl 0.9%) agaricus extract group was agaricus extract and streptozotocin treatment group was treated with streptozotocin treatment and saline was streptozotocin + agaricus extract treatment group was treated with streptozotocin treatment. Oral administration was carried out in the morning and afternoon while maintaining a certain time according to the weight of the food. Food (feed, water) and water were administered for 4 weeks as in the normal group.

Experimental results showed that agaricus extract (2.5 / kg) + streptozotocin (40mg / kg) group resulted in an effective blood glucose reduction according to the administration period of agaricus extract, which caused acute necrosis and sudden necrosis of pancreatic cells (β-Cell) in white paper. It has been shown to have the effect of preventing and protecting destruction and improving hyperglycemic diseases. Especially, it has great significance as it has the effect of improving liver function which seems to prevent the complications caused by hyperglycemic diseases.

Looking specifically at the present invention is the same as the embodiment.

Example 1) Sample Preparation

Experimental Animals: Six healthy white papers (Sprague-Dawley) with a body weight of about 200 g were used. Samples were started with a stable time of 1 week for in-lab environmental adaptation.

Normal group is divided into control group, normal group, agaricus extract (2.5 / g) group, streptozotocin (40mg / kg) group, agaricus extract (2.5 / kg) + streptozotocin (40mg / kg) group. Dietary intake without change of life, control was saline solution (Nacl 0.9%), agaricus extract group was agaricus extract, streptozotocin group was treated with streptozotocin treatment, saline was added to agaricus extract + streptozotocin group was treated with streptozotocin treatment. Maintain a certain time according to the prescribed amount was administered orally through the morning and afternoon, and food (water, feed), etc. were administered for 4 weeks to freely intake like the normal group.

Preparation and Administration of Streptozotocin: Streptozotocin, known as a diabetes-inducing agent with alloxan, is currently used in a variety of Sigma products.

Saline: A sterilized product containing 0.9% Nacl was used by Sino Pharmaceutical (Korea).

Agaricus Mushroom Extract Preparation: Shaking 200 g / 70% Ethanol 2.0L of Agaricus mushroom (dried) at room temperature and extracting the extract for 3 days after removing the solvent using a reduced pressure concentrator to obtain 70 g of blackish brown syrup extract. Saline was diluted and the sample was prepared using the same method as above and used again.

Example 2 Effect of Agaricus Extract Administration on Hypoglycemia

The animals were fasted for 12 hours prior to blood collection, and blood was collected through cardiac penetrating under Ether anesthesia. The collected blood was rapidly collected using centrifuge for 10 minutes at 2500-3000 rpm, using fresh serum. Results: normal group 105.3 ± 3.70, control group 110.5 ± 4.23, agaricus extract (2.5 / kg) group 98.7 ± 2.56, streptozotocin (40mg / kg) group 326.9 ± 12.65, agaricus mushroom extract (2.5g / kg) + streptococcus Jotocin (4mg / kg) It is difficult to clarify the significance of blood glucose changes in normal group, control group, and agaricus extract with 135.6 ± 6.93, but it was slightly (12mg / ㎗) in agaricus mushroom-treated group compared to normal group and control group. The agaricus mushroom extract may be due to the activation of somatic cells, and it may be possible to live a normal life, especially against high blood sugar caused by streptozotocin. As a result of obtaining a significant decrease in blood glucose levels to maintain a blood sugar level, the agaricus mushroom extract acted to prevent and activate necrosis in somatic cells (β-Cell). Table 1

Effect of Agaricus Mushroom Extracts on Hyperglycemia of Streptozotocin-induced Rats Drug Dose Blood glucose (mg / dl) Normal Basal diet 105.3 ± 3.70 Control 0.9% Nacl 110.5 ± 4.53 Agaricus Extract Group 2.5g / kg 98.7 ± 2.56 Streptozotocin 40mg / kg 326.9 ± 12.65 Agaricus extract group + Streptozotocin group 2.5g / kg + 40mg / kg 145.6 ± 6.13

This data is the result of 3 repeated experiments and is expressed as mean ± SE (standard deviation) (Same 2, 3 same) Mean ± SD

* Significant at p <0.05 vs. control group

Example 3 Effect of Agaricus Mushroom Extract on ALT (s-GPT) Enzyme Activity

Reitman-Frankel unit / ㎗ qjqdmfh ALT (s-GPT) was measured, normal group 40.3 ± 2.3, control group 43.4 ± 2.95, agaricus extract group 38.7 ± 2.53, streptozotocin group 89.7 ± .76, agaricus mushroom extract + streptozotocin group 44.3 ± 2.21 did not show enzyme changes in the normal, control and agaricus mushroom extract groups. It seems that long-term administration of agaricus mushroom extract does not show side effects.

On the other hand, the streptozotocin group showed a secondary complication due to the change of enzymes that suspect liver failure along with the incidence of hyperglycemia. However, in the agaricus extract + streptozotocin group, the enzyme elevation was similar to that of the normal group. Inhibition of hepatic impairment caused by complications in hyperglycemic diseases was obtained. In particular, hyperglycemic disease was suppressed by inhibiting ALT (s-GPT) enzyme, which is most sensitive to hepatic impairment and elevated liver function. Indirectly proved that it can be used to improve complications.

Effect of Agaricus Mushroom Extract on ALT (s-GPT) Enzyme Activity in Hyperglycemic Diseases of Rats Drug Dose Enzymatic activities (ALT) Normal Basal diet 40.3 ± 2.3 Control 0.9% Nacl 43.4 ± 2.95 Agaricus Extract Group 2.5g / kg 38.7 ± 2.53 Streptozotocin 40mg / kg 89.7 ± 5.76 Agaricus extract + Streptozotocin group 2.5g / kg + 40mg / kg 44.3 ± 2.21

Mean ± SD

* Significant at p <0.05 vs. control group

Example 4 Effect of Agaricus Mushroom Extract on AST (s-GOT) Enzyme Activity

AST (s-GOT) measurement by Retiman-Frankel unit / ㎗ method, normal group 78.27 ± 1.74, control group 82.3 ± 2.12, agaricus mushroom extract group 76.6 ± 1.83, streptozotocin group 125.8 ± 4.86, agaricus mushroom extract + streptozototo Changes in AST enzyme in the normal group, the control group, and the Agaricus mushroom extract group did not appear to have a significant change in the Shin group 86.2 ± 2.45, and the results in the Agaricus mushroom extract group did not affect the side effects of long-term administration as ALT. Appeared.

In the streptozotocin group, a combination of ALT enzymes leads to an increase in secondary complications, and the agaricus mushroom extract + streptozotocin group suppresses the increase in enzymes similar to normal and control groups. It was once again confirmed that it is commercially available as a blocking material.

Effect of Agaricus Mushroom Extracts on AST (s-GOT) Enzyme Activity in Hyperglycemic Diseases of Rats Drug Dose Enzymatic activities (GOT) Normal Basal diet 78.27 ± 1.74 Control 0.9% Nacl 82.3 ± 2.12 Agaricus Extract Group 2.5g / kg 76.6 ± 1.83 Streptozotocin 40mg / kg 125.8 ± 4.86 Agaricus extract + Streptozotocin 2.5g / kg + 40mg / kg 86.2 ± 2.45

Mean ± SD

* Significant at p <0.05 vs. control group

Treated with a single agent containing agaricus mushroom extract as an essential ingredient, it shows excellent efficacy in inhibiting blood sugar rise in hyperglycemic diseases and improving and assisting liver disorders due to complications. It can be useful.

1 shows pancreatic cells of control rats

Figure 2 shows the pancreatic cells of rats administered with Agaricus mushroom extract alone

3 shows pancreatic cells of mice treated with streptozotocin alone

Figure 4 shows the pancreatic cells of mice treated with streptozotocin with administration of agaricus mushroom extract

Claims (2)

Manufacturing method of health functional food with the function of agaricus mushroom extract as an essential ingredient as an adjuvant to improve hyperglycemic diseases and prevent complications The use of the health functional food for improving hyperglycemic diseases, supplementing and preventing complications by using the additive which is allowed as food for the agaricus mushroom extract of claim 1